ATOPIC DERMATITIS (ECZEMA)

This study tests whether IMG-007 can safely reduce eczema symptoms like itching and redness in adults with moderate-to-severe disease who haven't responded well to topical treatments. About 405 participants will receive either the drug or a placebo, and researchers will measure s…

This study tests whether adults with well-controlled eczema can safely extend the time between doses of the drug Dupilumab (Dupixent). 216 participants will be randomly assigned to receive the drug every 2, 3, or 4 weeks. Researchers will compare eczema severity and quality of li…

This study tests a daily pill called soquelitinib in 200 adults with moderate to severe atopic dermatitis (eczema). Participants take either the drug or a placebo for 12 weeks, and doctors track skin improvements and side effects. The goal is to see if soquelitinib can safely red…

This international study observes how people with atopic dermatitis (eczema) access healthcare, what treatments they receive, and how the disease affects their daily lives. Researchers will collect data from routine medical records of about 9,600 participants across multiple coun…

This study looks at whether tiny DNA fragments released from damaged skin cells into the blood can help measure eczema severity. Researchers will compare blood and skin samples from 80 adults with eczema and healthy volunteers. The goal is to understand how these DNA fragments tr…

This study tests whether a special microscope (reflectance confocal microscopy) can detect skin changes in people with moderate-to-severe eczema who are taking tralokinumab. The drug blocks a protein involved in inflammation and is already known to help eczema. Researchers want t…